Saturday 17 October 2026
Export ASBP’s income statement to Excel — free account
Aspire-Lakewood Holdings, Inc.
ASBP Healthcare Biotechnology
Aspire-Lakewood Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6,200.00. In the quarter to June 2026, EPS grew 97.5%, free cash flow fell 85.5% and total debt fell 79.7%, each against the same quarter a year earlier.
8.78
0.14
+1.62%
Follow ASBP
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.15 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
56.73 | 0.00 | 0.00 | 0.00 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(2.62) | (0.05) | (0.28) | (0.31) | |
P/B ratio |
0.47 | 0.04 | 0.00 | 0.00 | |
Price to Tangible BV |
0.47 | 0.04 | 0.00 | 0.00 | |
EV/Sales |
(39.24) | 0.00 | 0.00 | 0.00 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
0.53 | 0.47 | (0.42) | (1.32) | |
EV/FCF |
0.53 | 0.47 | (0.42) | (1.32) | |
Quick Ratio |
7.22 | 1.86 | 0.13 | 0.14 | |
Current Ratio |
7.99 | 2.26 | 0.17 | 0.17 | |
Net Debt/EBITDA |
4.54 | 94.01 | 0.43 | (3.75) | |
Debt/Assets |
0.00% | 0.00% | 212.66% | 259.66% | |
Debt/Equity |
0.00 | 0.00 | (0.44) | (0.54) | |
Asset Turnover |
0.01 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.67 | 0.94 | 0.20 | 0.60 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
— | (1.03) | (0.30) | (0.77) | |
Research and Development Expense of Revenue |
370.05% | 1,044.72% | 2,325.58% | 10,942.11% | |
Selling, General and Administrative Expense of Revenue |
3,463.07% | 4,771.83% | 40,660.47% | 49,394.74% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
228.37% | 47.18% | 0.00% | 0.00% | |
Graham Net Nets |
2.11 | 23.97 | (24.25) | (33.78) | |
Graham Number |
96.25 | 0.00 | 1,193.46 | 1,992.48 | |
Earnings Yield |
680.69% | (1,017.41%) | (9,363.89%) | (7,693.36%) | |
Free Cash Flow Yield |
(129.65%) | (3,847.87%) | (1,872.45%) | (1,035.68%) | |
Revenue per Share |
0.06 | 0.18 | 0.09 | 0.05 | |
Operating CF per Share |
(2.04) | (19.39) | (18.63) | (26.79) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(2.04) | (19.39) | (18.63) | (26.79) | |
Cash per Share |
11.72 | 37.38 | 20.16 | 47.29 | |
Shareholders Equity per Share |
11.33 | 24.69 | (128.04) | (278.33) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
11.33 | 24.69 | (128.04) | (278.33) | |
Free Cash Flow |
(2.12) | (3.04) | (0.93) | (1.10) | |
Working Capital |
11.78 | 3.96 | (6.28) | (11.46) | |
Net Current Asset Value |
11.68 | 3.87 | (6.38) | (11.47) | |
EV/EBIT |
0.52 | 0.53 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
1.35 | 1.37 | 0.66 | 0.98 | |
Average Assets |
7.26 | 4.54 | 0.73 | 4.53 | |
Average Common Equity |
1.07 | (2.04) | (3.96) | (8.99) |
Columns are period end dates